Sean A. McCarthy, the CEO of $CTMX, sold 37,656 shares of the company on 03-18-2025 for an estimated $22,555. We received data on the trade from a recent SEC filing ...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) earns a spot on our list of the best penny stocks set to explode. As of April 8, 2026, all covering analysts rate CytomX Therapeutics, Inc. (NASDAQ:CTMX) as a ...
Christopher Ogden, the Chief Financial Officer of $CTMX, sold 10,614 shares of the company on 06-16-2025 for an estimated $28,539. We received data on the trade from ...
CytomX Therapeutics presents a trade opportunity centered on upcoming Q1'26 clinical data for its masked, EpCAM-targeting, antibody-drug conjugate. Previous phase 1 data showed a compelling response ...
Shares of CytomX TherapeuticsCTMX soared 44.2% on Monday after the company reported positive phase I expansion data for its EpCAM-targeting PROBODY ADC, varsetatug masetecan (Varseta-M), in late-line ...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the popular penny stocks on Robinhood to buy. On March 23, Piper Sandler analyst Joseph Catanzaro raised his price target on CytomX Therapeutics, Inc.
CytomX Therapeutics (NASDAQ:CTMX) just reported results for the second quarter of 2024. CytomX Therapeutics reported earnings per share of -8 cents. This was above the analyst estimate for EPS of -14 ...
CytomX Therapeutics, Inc.‘s (NASDAQ:CTMX) share price was up 94.46% at last check on Monday. The stock surged after the company reported interim Phase 1 data for its EpCAM PROBODY ADC candidate, ...
CytomX Therapeutics, Inc. (NASDAQ:CTMX) earns a spot on our list of the best penny stocks set to explode. As of April 8, 2026, all covering analysts rate CytomX Therapeutics, Inc. (NASDAQ:CTMX) as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results